SG11201601202WA - Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof - Google Patents
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereofInfo
- Publication number
- SG11201601202WA SG11201601202WA SG11201601202WA SG11201601202WA SG11201601202WA SG 11201601202W A SG11201601202W A SG 11201601202WA SG 11201601202W A SG11201601202W A SG 11201601202WA SG 11201601202W A SG11201601202W A SG 11201601202WA SG 11201601202W A SG11201601202W A SG 11201601202WA
- Authority
- SG
- Singapore
- Prior art keywords
- analogs
- treating
- methods
- endothelial dysfunction
- bardoxolone methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869527P | 2013-08-23 | 2013-08-23 | |
| PCT/US2014/052382 WO2015027206A1 (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601202WA true SG11201601202WA (en) | 2016-03-30 |
Family
ID=51794949
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601202WA SG11201601202WA (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| SG10201906113RA SG10201906113RA (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906113RA SG10201906113RA (en) | 2013-08-23 | 2014-08-22 | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20150080465A1 (en) |
| EP (1) | EP3035937A1 (en) |
| JP (3) | JP6564372B2 (en) |
| KR (1) | KR102322057B1 (en) |
| CN (2) | CN105517554B (en) |
| AU (2) | AU2014308600B2 (en) |
| BR (1) | BR112016003454B1 (en) |
| CA (1) | CA2921386A1 (en) |
| CL (1) | CL2016000405A1 (en) |
| EA (1) | EA201690456A1 (en) |
| HK (1) | HK1223015A1 (en) |
| IL (3) | IL285832B2 (en) |
| MX (2) | MX2016002375A (en) |
| MY (1) | MY198522A (en) |
| NZ (4) | NZ630951A (en) |
| PH (1) | PH12016500358A1 (en) |
| SG (2) | SG11201601202WA (en) |
| TW (2) | TWI716341B (en) |
| WO (1) | WO2015027206A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
| MX2010011435A (en) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compounds including an anti-inflammatory pharmacore and methods of use. |
| CA2721838C (en) | 2008-04-18 | 2017-05-23 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| US8513436B2 (en) | 2010-12-17 | 2013-08-20 | Reata Pharmaceuticals, Inc. | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| WO2013163344A1 (en) | 2012-04-27 | 2013-10-31 | Reata Pharmaceuticals, Inc. | 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
| US9556222B2 (en) | 2012-06-15 | 2017-01-31 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| DK2892912T3 (en) | 2012-09-10 | 2019-06-24 | Reata Pharmaceuticals Inc | C17-ALKANDYLY AND ALKENEDIYOL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (en) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 2,2-difluoropropionamide derivative of methyl bardoxolone, polymorph thereof and use thereof |
| BR112016003454B1 (en) * | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | USE OF METHYL BARDOXOLONE COMPOUND |
| KR20240035818A (en) | 2015-02-12 | 2024-03-18 | 리아타 파마슈티컬즈, 아이엔씨. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| KR20180061251A (en) | 2015-09-23 | 2018-06-07 | 리아타 파마슈티컬즈, 아이엔씨. | C4-Modified Olenanoic acid Derivatives and Other Uses for the Inhibition of IL-17 |
| KR102486434B1 (en) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| CN106632574B (en) * | 2016-12-07 | 2018-05-29 | 广东天键生物科技有限公司 | A kind of compound, preparation method and the usage |
| TWI831738B (en) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES |
| WO2018200692A1 (en) * | 2017-04-26 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Methods and systems for virtual and augmented reality training for responding to emergency conditions |
| US11993574B2 (en) | 2018-06-15 | 2024-05-28 | Reata Pharmaceuticals, Inc | Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma |
| CA3114354A1 (en) * | 2018-09-28 | 2020-04-02 | Sichuan Haisco Pharmaceutical Co., Ltd. | Terpinoid derivatives and uses thereof |
| JPWO2020080482A1 (en) * | 2018-10-17 | 2021-09-09 | Kagami株式会社 | A method for validating renal function test results based on the amount of cystatin C in blood |
| CN114729001A (en) * | 2019-11-27 | 2022-07-08 | 鲁南制药集团股份有限公司 | Oleane phenylpropenamide derivative and preparation method and application thereof |
| AU2020408323A1 (en) | 2019-12-16 | 2022-08-11 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF) |
| WO2021202720A1 (en) * | 2020-04-01 | 2021-10-07 | Fronthera U.S. Pharmaceuticals Llc | Use of triterpenoid nrf2 inhibitors |
| US20230255982A1 (en) * | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
| CN111704647B (en) * | 2020-06-15 | 2021-10-22 | 中国人民解放军海军军医大学 | Triterpenoid derivatives and application thereof as programmed cell necrosis inhibitor |
| EP4259155A1 (en) | 2020-12-11 | 2023-10-18 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| US20220401396A1 (en) * | 2021-06-22 | 2022-12-22 | Asklepion Pharmaceuticals, Llc | Action of l-citrulline to prevent or treat endothelial dysfunction |
| CN114097807B (en) * | 2021-11-25 | 2023-05-05 | 兰州大学 | Use of bardoxolone compounds in resisting agricultural pathogenic fungi |
| CN116509874A (en) * | 2023-02-01 | 2023-08-01 | 潍坊医学院附属医院 | Application of methylbardoxolone in preparation of medicine for improving viral myocarditis or viral myocardial injury |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| AU658374B2 (en) | 1990-09-14 | 1995-04-13 | Biosite Diagnostics Incorporated | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| WO1992018868A1 (en) | 1991-04-10 | 1992-10-29 | Biosite Diagnostics Incorporated | Crosstalk inhibitors and their uses |
| DE69231382T2 (en) | 1991-04-12 | 2001-01-25 | Biosite Diagnostics Inc | NEW CONJUGATES AND TEST PROCEDURES FOR THE SIMULTANEOUS DETERMINATION OF MULTIPLE LIGANDS |
| US5885527A (en) | 1992-05-21 | 1999-03-23 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membrances |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| GB9212302D0 (en) | 1992-06-10 | 1992-07-22 | Applied Research Systems | Method for improving measurement precision in evanescent wave optical biosensor assays |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| WO2003059339A1 (en) | 2002-01-15 | 2003-07-24 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| CA2412856A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| CN1972684A (en) * | 2004-04-23 | 2007-05-30 | 细胞基因公司 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
| WO2008064133A1 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| US20080280377A1 (en) | 2007-05-08 | 2008-11-13 | Abbott Laboratories | Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009089545A1 (en) | 2008-01-11 | 2009-07-16 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
| MX2010011435A (en) | 2008-04-18 | 2011-01-25 | Reata Pharmaceuticals Inc | Compounds including an anti-inflammatory pharmacore and methods of use. |
| CN102164941B (en) | 2008-04-18 | 2015-05-27 | 里亚塔医药公司 | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
| CA2721838C (en) | 2008-04-18 | 2017-05-23 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| WO2009146216A2 (en) * | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals. Inc. | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| BRPI0911422B8 (en) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals Inc | inflammatory antioxidant modulating compounds, pharmaceutical composition and their uses |
| PL3254675T3 (en) | 2009-02-13 | 2019-09-30 | Reata Pharmaceuticals, Inc. | Delayed release, oral dosage compositions that contain amorphous cddo-me |
| KR101819699B1 (en) * | 2010-04-12 | 2018-01-17 | 리아타 파마슈티컬즈, 아이엔씨. | Method of treating obesity using antioxidant inflammation modulators |
| BR112016003454B1 (en) * | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | USE OF METHYL BARDOXOLONE COMPOUND |
| US20230255982A1 (en) * | 2020-05-09 | 2023-08-17 | Reata Pharmaceuticals Holdings, LLC | Methods of treating covid-19 using bardoxolone methyl or analogs thereof |
-
2014
- 2014-08-22 BR BR112016003454-6A patent/BR112016003454B1/en active IP Right Grant
- 2014-08-22 US US14/466,495 patent/US20150080465A1/en not_active Abandoned
- 2014-08-22 CA CA2921386A patent/CA2921386A1/en active Pending
- 2014-08-22 NZ NZ630951A patent/NZ630951A/en unknown
- 2014-08-22 CN CN201480049377.4A patent/CN105517554B/en active Active
- 2014-08-22 WO PCT/US2014/052382 patent/WO2015027206A1/en active Application Filing
- 2014-08-22 NZ NZ744036A patent/NZ744036A/en unknown
- 2014-08-22 NZ NZ756256A patent/NZ756256A/en unknown
- 2014-08-22 IL IL285832A patent/IL285832B2/en unknown
- 2014-08-22 JP JP2016536495A patent/JP6564372B2/en active Active
- 2014-08-22 SG SG11201601202WA patent/SG11201601202WA/en unknown
- 2014-08-22 EA EA201690456A patent/EA201690456A1/en unknown
- 2014-08-22 TW TW103129094A patent/TWI716341B/en active
- 2014-08-22 EP EP14789437.2A patent/EP3035937A1/en active Pending
- 2014-08-22 CN CN202110101573.3A patent/CN112870202A/en active Pending
- 2014-08-22 MX MX2016002375A patent/MX2016002375A/en unknown
- 2014-08-22 KR KR1020167006597A patent/KR102322057B1/en active IP Right Grant
- 2014-08-22 NZ NZ774222A patent/NZ774222A/en unknown
- 2014-08-22 MY MYPI2016000331A patent/MY198522A/en unknown
- 2014-08-22 TW TW108134064A patent/TWI717026B/en active
- 2014-08-22 AU AU2014308600A patent/AU2014308600B2/en active Active
- 2014-08-22 SG SG10201906113RA patent/SG10201906113RA/en unknown
-
2016
- 2016-02-17 IL IL244171A patent/IL244171B/en active IP Right Grant
- 2016-02-17 IL IL272242A patent/IL272242B/en unknown
- 2016-02-23 CL CL2016000405A patent/CL2016000405A1/en unknown
- 2016-02-23 PH PH12016500358A patent/PH12016500358A1/en unknown
- 2016-02-23 MX MX2021002897A patent/MX2021002897A/en unknown
- 2016-09-23 HK HK16111185.4A patent/HK1223015A1/en unknown
-
2018
- 2018-10-11 US US16/157,225 patent/US20190091194A1/en not_active Abandoned
- 2018-11-27 JP JP2018220800A patent/JP6526306B2/en active Active
-
2019
- 2019-04-10 JP JP2019074559A patent/JP6701407B2/en active Active
-
2020
- 2020-05-28 AU AU2020203510A patent/AU2020203510B2/en active Active
-
2023
- 2023-06-09 US US18/332,603 patent/US20240115542A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285832A (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| IL286888A (en) | Use of pridopidine to treat depression or anxiety | |
| HK1222793A1 (en) | Methods and compositions for inhibition of bromodomain-containing proteins | |
| HK1217908A1 (en) | Methods of treating cholangiocarcinoma | |
| HK1220995A1 (en) | Microbial-based waste water treatment compositions and methods of use thereof | |
| HK1225654A1 (en) | Compositions and methods for the treatment of presbyopia | |
| HK1217428A1 (en) | Substituted benzoxazoles and methods of use thereof | |
| HK1253049A1 (en) | Glycan-interacting compounds and methods of use | |
| EP2970317A4 (en) | Pyrimido-diazepinone compounds and methods of treating disorders | |
| PT2948448T (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions | |
| EP2964651A4 (en) | Bmp inhibitors and methods of use thereof | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| HK1221611A1 (en) | Methods of maintaining and improving muscle function | |
| EP2970311A4 (en) | Bmp inhibitors and methods of use thereof | |
| IL282482A (en) | Protoxin-ii variants and methods of use | |
| HK1224210A1 (en) | Methods and compositions for treatment of fibrosis | |
| HK1221641A1 (en) | Vaccine composition and method of use | |
| IL282508A (en) | Protoxin-ii variants and methods of use | |
| HK1224307A1 (en) | Protoxin-ii variants and methods of use -ii | |
| HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| SG10201708272SA (en) | Method of Viral Inhibition | |
| TH1401007179A (en) | Its composition and use for prevention and treatment of hepatitis B | |
| GB201321848D0 (en) | Lock means and method of use thereof | |
| GB201216401D0 (en) | Methods of treating mitochondrial dysfunction | |
| GB201310349D0 (en) | Composition and method of use thereof |